Today: 7 February 2026
Subscribe

Nike Stock (NKE) Jumps on Tim Cook’s $3M Share Buy as Turnaround Pressures Mount: News, Forecasts and Analysis for Dec. 24, 2025

Nike Stock (NKE) Jumps on Tim Cook’s $3M Share Buy as Turnaround Pressures Mount: News, Forecasts and Analysis for Dec. 24, 2025

Nike, Inc. (NYSE: NKE) stock is getting a rare kind of holiday-season lift: a high-profile insider purchase. In the holiday-shortened U.S. trading session on Wednesday, December 24, 2025, shares climbed roughly 4%–5% after filings showed Apple CEO Tim Cook—also Nike’s long-time board member and lead independent director—bought about $3 million worth of Nike shares on the open market. Reuters+1 The move arrives at a sensitive moment for investors. Nike shares had fallen sharply after the company’s latest quarterly results and guidance, as management works through a wide-ranging reset under CEO Elliott Hill. Cook’s purchase doesn’t erase the fundamentals overnight—but it
24 December 2025
··
Home Depot Stock (HD) News Today, Dec. 24, 2025: Price Action, Analyst Forecasts, and What Investors Are Watching

Home Depot Stock (HD) News Today, Dec. 24, 2025: Price Action, Analyst Forecasts, and What Investors Are Watching

Home Depot, Inc. (NYSE: HD) is trading through a shortened Christmas Eve session with investors juggling mixed signals: upbeat Wall Street ratings, cautious earnings-revision trends, and a steady drumbeat of institutional-position headlines. Meanwhile, the broader market’s “Santa rally” narrative is picking up steam as the S&P 500 notched a fresh record intraday high on Wednesday. Reuters+1 As of the latest available trade on December 24, 2025, HD shares were around $347.51, up roughly 0.7% on the day, after opening near $344 and trading in the mid-$340s range. MarketWatch Below is a complete roundup of the key HD stock news, forecasts,
24 December 2025
·
Procter & Gamble (PG) Stock Today: Analyst Upgrades, Tariff Pressures, and a CEO Change Set the Tone for 2026

Procter & Gamble (PG) Stock Today: Analyst Upgrades, Tariff Pressures, and a CEO Change Set the Tone for 2026

December 24, 2025 — Procter & Gamble (NYSE: PG) is ending 2025 in a familiar role for markets: a defensive bellwether that investors watch closely for clues about consumer demand, pricing power, and how quickly households are trading down—or trading up—when the economy gets choppy. On December 24, 2025, with U.S. markets operating in a holiday-shortened session and broad indexes still hovering near record territory, P&G stock is trying to stabilize after a rough stretch that pushed shares toward early-December lows. Investopedia+1 Below is what’s moving Procter & Gamble stock right now, what Wall Street is forecasting, and the specific
24 December 2025
·
Polestar Stock (PSNY) Surges on Fresh Funding: Latest News, Analyst Forecasts, and What Investors Are Watching (Dec. 24, 2025)

Polestar Stock (PSNY) Surges on Fresh Funding: Latest News, Analyst Forecasts, and What Investors Are Watching (Dec. 24, 2025)

Polestar Automotive Holding UK PLC (Nasdaq: PSNY) is back in the market spotlight on December 24, 2025, with the stock rallying sharply as investors digest a string of balance-sheet moves designed to extend liquidity, reduce leverage, and keep the company’s Nasdaq listing in good standing. Business Wire+2Reuters+2 The quick version: PSNY traded around $17.09, up roughly 13% on the day, after Polestar announced $300 million in new equity, a plan for ~$300 million of debt to convert into equity, and a Geely-backed term loan facility of up to $600 million. Those are big numbers for a company that has been
24 December 2025
··
Merck Stock Forecast and News Roundup for December 24, 2025: MRK Hits a New 52-Week High as Wall Street Reprices 2026 Catalysts

Merck Stock Forecast and News Roundup for December 24, 2025: MRK Hits a New 52-Week High as Wall Street Reprices 2026 Catalysts

Merck & Company, Inc. stock is ending 2025 on a strong note. On December 24, 2025, shares of Merck (MRK) pushed to a fresh 12‑month high around the $106 level, extending a powerful late‑year rally that has put the pharma bellwether back in the spotlight. MarketBeat+2Investing.com+2 This move isn’t happening in a vacuum. Today’s MRK price action sits at the intersection of three market themes that have dominated Merck headlines into Christmas Eve: Below is a comprehensive, publication-ready roundup of the current news, forecasts, and analysis investors are reading as of December 24, 2025, and what it could mean for
24 December 2025
··
Edgewise Therapeutics Stock (EWTX) Jumps on EDG-7500 CIRRUS-HCM Update: Dec. 24, 2025 News, Analyst Forecasts, and Key Catalysts

Edgewise Therapeutics Stock (EWTX) Jumps on EDG-7500 CIRRUS-HCM Update: Dec. 24, 2025 News, Analyst Forecasts, and Key Catalysts

Edgewise Therapeutics, Inc. (NASDAQ: EWTX) stock surged in intraday trading on Wednesday, December 24, 2025, after the company released a fresh update on EDG-7500, its investigational therapy for hypertrophic cardiomyopathy (HCM). By late morning, shares were trading around $26.37—up roughly 21% versus the prior close—after swinging between about $21.30 and $27.05 on the day, with volume above 2.2 million shares. The move follows a company announcement that it has completed Parts B and C of its Phase 2 CIRRUS-HCM trial and reported favorable interim safety observations from Part D—an update that several market outlets characterized as a meaningful de-risking moment
24 December 2025
·
Johnson & Johnson Stock Today: JNJ Holds Near $207 on Dec. 24, 2025 as Talc Verdict, Drug-Price Pressure and Q4 Earnings Take Center Stage

Johnson & Johnson Stock Today: JNJ Holds Near $207 on Dec. 24, 2025 as Talc Verdict, Drug-Price Pressure and Q4 Earnings Take Center Stage

Johnson & Johnson (NYSE: JNJ) is trading through a holiday-shortened Christmas Eve session with investors balancing a familiar mix of defensive appeal and headline risk. On Wednesday, December 24, 2025, J&J shares hovered around $207 in late-morning trade, keeping the healthcare bellwether close to its recent highs even as the company faces fresh legal scrutiny and renewed policy pressure on U.S. drug pricing. StockAnalysis The immediate backdrop matters: U.S. markets are closing early at 1 p.m. ET for Christmas Eve, a schedule that can amplify moves and distort volume signals—especially for mega-caps like J&J that often act as “parking spots”
24 December 2025
···
Citigroup Stock News (NYSE: C) on Dec. 24, 2025: Regulatory Relief, Banamex Progress, and Wall Street Forecasts for 2026

Citigroup Stock News (NYSE: C) on Dec. 24, 2025: Regulatory Relief, Banamex Progress, and Wall Street Forecasts for 2026

NEW YORK — Citigroup, Inc. (NYSE: C) is closing out 2025 with a resurgence that has put C stock back on many investors’ watchlists. In the holiday-shortened session on Wednesday, Dec. 24, 2025, Wall Street traded close to record territory amid thin volumes, while bank shares remained in focus after a string of December headlines around regulatory progress, strategic streamlining, and improving profitability expectations. Reuters For Citigroup specifically, the story going into year-end is less about a single “Christmas Eve catalyst” and more about a stack of developments in the past two weeks that has helped reframe the Citi turnaround
24 December 2025
·
ServiceNow Stock (NYSE: NOW) News Today: $7.75B Armis Deal, CEO Contract Extension, and 2026 Analyst Forecasts (Dec. 24, 2025)

ServiceNow Stock (NYSE: NOW) News Today: $7.75B Armis Deal, CEO Contract Extension, and 2026 Analyst Forecasts (Dec. 24, 2025)

ServiceNow, Inc. (NYSE: NOW) is back in the spotlight on December 24, 2025, as investors weigh two major developments: the company’s $7.75 billion all-cash agreement to acquire cybersecurity firm Armis and a new CEO contract extension for Bill McDermott through 2030. Add in the recent 5‑for‑1 stock split that reset the share price and made older price targets harder to compare, and you have a stock that’s suddenly a daily headline again. Below is a detailed, publication-ready breakdown of today’s ServiceNow stock news, what analysts are forecasting, and the key bull/bear arguments shaping NOW’s outlook into 2026. ServiceNow stock price
24 December 2025
··
Warner Bros. Discovery (WBD) Series A Stock: Latest News, Deal Battle Updates, and Wall Street Forecasts on Dec. 24, 2025

Warner Bros. Discovery (WBD) Series A Stock: Latest News, Deal Battle Updates, and Wall Street Forecasts on Dec. 24, 2025

Warner Bros. Discovery, Inc. Series A Common Stock (NASDAQ: WBD) is ending 2025 as one of the most deal-driven names in U.S. media—caught between a signed Netflix agreement and an aggressive, sweetened hostile bid from Paramount Skydance. On December 24, 2025, WBD shares traded around $29.18, positioning the stock neatly between Netflix’s $27.75 per share cash-and-stock structure (plus a planned networks spin-off) and Paramount Skydance’s $30.00 per share all-cash tender offer for the entire company. Reuters+1 That “in-the-middle” price is the market’s way of saying: this is no longer just a fundamentals story. It’s a high-stakes, multi-path outcome story—one where
24 December 2025
·
Exxon Mobil Stock (XOM) News and Forecast for Dec. 24, 2025: Sakhalin-1 Deadline Extended, Oil Prices Rebound, and Analysts See More Upside

Exxon Mobil Stock (XOM) News and Forecast for Dec. 24, 2025: Sakhalin-1 Deadline Extended, Oil Prices Rebound, and Analysts See More Upside

Exxon Mobil Corporation stock (NYSE: XOM) traded around $119.62 in holiday-thinned action on Wednesday, Dec. 24, 2025, as investors balanced a fresh geopolitical headline tied directly to Exxon’s long-running Russia exit, a late-December rebound in crude prices, and a steady drumbeat of analyst targets clustering in the low $130s. With U.S. markets operating on a shortened Christmas Eve session (stocks closing early), price moves across energy names are being amplified by lighter volumes—often making “headline sensitivity” more pronounced than on a normal trading day. Investopedia Below is what matters most for Exxon Mobil stock today: the Russia/Sakhalin-1 update, the crude-oil
24 December 2025
···
Recursion Pharmaceuticals (RXRX) Stock News Today: Analysts Refocus on REC-4881 Data, ARK Buying, and a 2026 CEO Transition

Recursion Pharmaceuticals (RXRX) Stock News Today: Analysts Refocus on REC-4881 Data, ARK Buying, and a 2026 CEO Transition

Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) is ending 2025 with something investors in AI-driven biotech rarely get in the same month: fresh clinical momentum, a high-profile Wall Street upgrade, and renewed attention from Cathie Wood’s ARK funds—all playing out during a shortened Christmas Eve trading session. As of December 24, 2025, RXRX stock is trading around $4.37, up modestly on the day, with a market capitalization near $2.12 billion. That price level may look quiet at a glance—until you zoom out to the drivers behind the tape: REC-4881’s Phase 1b/2 TUPELO readout in familial adenomatous polyposis (FAP), J.P. Morgan’s upgrade, ARK’s
24 December 2025
·
1 … 1,266 1,267 1,268 1,269 1,270 … 2,716

Stock Market Today

Kenvue stock price holds near $18 as Kimberly-Clark deal math tightens — what to watch next week

Kenvue stock price holds near $18 as Kimberly-Clark deal math tightens — what to watch next week

7 February 2026
Kenvue shares closed Friday at $18.13, up 0.33%, with about 63.5 million shares traded. The Kimberly-Clark offer values Kenvue at roughly $18.76 per share, leaving a deal spread of about 3%. Both companies’ shareholders approved the merger, which is expected to close in the second half of 2026 pending regulatory approvals. Kenvue’s dividend record date is Feb. 11, with earnings due Feb. 17.
Go toTop